[Skip to Content]
[Skip to Content Landing]
Article
December 1991

Prospective Evaluation of the Use of Antigen-Specific Immune Complexes in Predicting the Development of Recurrent Melanoma

Author Affiliations

From the Division of Surgical Oncology, John Wayne Cancer Clinic, Jonsson Comprehensive Cancer Center, UCLA School of Medicine (Drs Wong, Skinner, Foshag, and Morton and Ms Xu), and the Surgical Service, Section of Surgical Oncology, Sepulveda (Calif) Veterans Administration Medical Center (Dr Wong).

Arch Surg. 1991;126(12):1450-1454. doi:10.1001/archsurg.1991.01410360020004
Abstract

• We previously demonstrated that the antigen-specific immune complexes captured by the monoclonal antibody MAb JSI in a sandwich enzyme-linked immunosorbent assay were associated with recurrent melanoma. To determine the potential use of antigen-specific immune complex analysis in predicting the development of recurrent melanoma, we prospectively analyzed serum obtained from patients with melanoma following surgical treatment. Two hundred fifty-three patients have been followed up for a median of 25 months (range, 17 to 29 months). Seventy-seven patients (30%) have developed recurrent melanoma. Antigen-specific immune complexes correlated with the stage of disease at time of entry into the study. The absence of antigen-specific immune complexes in postoperative serum samples is predictive of a disease-free status. Long-term follow-up will define the false-positive rate of antigen-specific immune complex analysis. Continued refinement of this approach should lead to clinically useful methodology to monitor human melanoma.

(Arch Surg. 1991;126:1450-1454)

×